Skip to main navigation Skip to search Skip to main content

An Open-Label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatica

Grants and Contracts Details

StatusFinished
Effective start/end date3/24/20 → 1/11/25

Funding

  • Medpace Inc: $108,565.00